Combo Tx Improves PFS in High-Risk CLL

(MedPage Today) -- At the American Society of Clinical Oncology virtual annual meeting, the GENUINE trial evaluated the addition of ublituximab to ibrutinib in previously treated patients with high-risk relapsed/refractory chronic lymphocytic leukemia...